Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis

PLoS Pathogens

Volumn 9, Issue 4, 2013, Pages

  Angelini, Daniela F ^a   Serafini, Barbara ^b   Piras, Eleonora ^a   Severa, Martina ^b   Coccia, Eliana M ^b   Rosicarelli, Barbara ^b   Ruggieri, Serena ^c   Gasperini, Claudio ^d   Buttari, Fabio ^e   Centonze, Diego ^e   Mechelli, Rosella ^f   Salvetti, Marco ^f   Borsellino, Giovanna ^a   Aloisi, Francesca ^b   Battistini, Luca ^a  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; EPSTEIN BARR VIRUS ANTIGEN; HLA ANTIGEN CLASS 1; IMMEDIATE EARLY PROTEIN BZLF1; NATALIZUMAB;

ADULT; ARTICLE; AUTOPSY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; CD8-POSITIVE T-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SEROEPIDEMIOLOGIC STUDIES; TRANS-ACTIVATORS; YOUNG ADULT;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4;

EID: 84876832178     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003220     Document Type: Article

References (65)

1. Compston A, Coles A, (2008) Multiple sclerosis. Lancet 372: 1502-1517.
2. Nylander A, Hafler DA, (2012) Multiple sclerosis. J Clin Invest 122: 1180-1188.
3. Lünemann JD, Münz C, (2009) EBV in MS: guilty by association? Trends Immunol 30: 243-248.
4. Ascherio A, Munger KL, (2010) Epstein-Barr virus infection and multiple sclerosis: a review. J Neuroimmune Pharmacol 5: 271-277.
5. Pender MP, (2011) The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 17: 351-367.
6. Thorley-Lawson DA, (2001) Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 1: 75-82.
7. James JA, Robertson JM, (2012) Lupus and epstein-barr. Curr Opin Rheumatol 24: 383-388.
8. Posnett DN, (2008) Herpesviruses and autoimmunity. Curr Opin Investig Drugs 9: 505-514.
9. Sumaya CV, Myers LW, Ellison GW, Ench Y, (1985) Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol 17: 371-377.
10. Sundström P, Juto P, Wadell G, Hallmans G, Svenningsson A, et al. (2004) An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 62: 2277-2282.
11. Levin LI, Munger KL, Rubertone MV, et al. (2005) Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293: 2496-500.
12. Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, et al. (2007) Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 6: 773-781.
13. Lünemann JD, Huppke P, Roberts S, Brück W, Gärtner J, Münz C, (2008) Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology 71: 1033-1035.
14. Mechelli R, Anderson J, Vittori D, Coarelli G, Annibali V, et al. (2011) Epstein-Barr virus nuclear antigen-1 B-cell epitopes in multiple sclerosis twins. Mult Scler 17: 1290-1294.
15. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernán MA, et al. (2001) Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286: 3083-3088.
16. Lünemann JD, Tintoré M, Messmer B, Strowig T, Rovira A, et al. (2010) Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol 67: 159-169.
17. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, et al. (2010) an updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS One 5 (9) (): e12496.
18. Lünemann JD, Edwards N, Muraro PA, Hayashi S, Cohen JI, et al. (2006) Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129: 1493-506.
19. Höllsberg P, Hansen HJ, Haahr S, (2003) Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol 132: 137-143.
20. Cepok S, Zhou D, Srivastava R, Nessler S, Stei S, et al. (2005) Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 115: 1352-1360.
21. Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, et al. (2008) Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 131: 1712-1721.
22. Pender MP, Csurhes PA, Lenarczyk A, Pfluger CM, Burrows SR, (2009) Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. J Neurol Neurosurg Psychiatry 80: 498-505.
23. Jilek S, Schluep M, Harari A, Canales M, Lysandropoulos A, et al. (2012) HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis. J Immunol 188: 4671-4680.
24. Pender MP, (2003) Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 24: 584-588.
25. Lünemann JD, Jelcić I, Roberts S, Lutterotti A, Tackenberg B, et al. (2008) EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 205: 1763-1773.
26. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, et al. (2002) A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 3: 940-943.
27. Lassmann H, Niedobitek G, Aloisi F, Middeldorp JM, (2011) NeuroproMiSe EBV Working Group (2011) Epstein-Barr virus in the multiple sclerosis brain: a controversial issue- report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain 134: 2772-2786.
28. Peferoen LA, Lamers F, Lodder LN, Gerritsen WH, Huitinga I, et al. (2010) Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain 133: 1-4.
29. Willis SN, Stadelmann C, Rodig SJ, et al. (2009) Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 132: 3318-3328.
30. Torkildsen O, Stansberg C, Angelskar SM, et al. (2010) Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathol 20: 720-729.
31. Sargsyan SA, Shearer AJ, Ritchie AM, et al. (2010) Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 74: 1127-1135.
32. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, et al. (2007) Dysregulated Epstein Barr virus infection in the multiple sclerosis brain. J Exp Med 204: 2899-2912.
33. Serafini B, Severa M, Columba-Cabezas S, Rosicarelli B, Veroni C, et al. (2010) Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol 69: 677-693.
34. Serafini B, Muzio L, Rosicarelli B, Aloisi F, (2013) Radioactive in situ hybridization for EBER supports presence of Epstein-Barr virus in the multiple sclerosis brain. Brain doi:10.1093/brain/aws315.
35. Tzartos JS, Khan G, Vossenkamper A, Cruz-Sadaba M, Lonardi S, et al. (2012) Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 78: 15-23.
36. Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, et al. (2009) Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 73: 32-38.
37. Buljevac D, van Doornum GJ, Flach HZ, Groen J, Osterhaus AD, et al. (2005) Epstein-Barr virus and disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 76: 1377-1381.
38. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, et al. (1992) Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 176: 157-168.
39. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, et al. (1997) Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 185: 1605-1617.
40. Palendira U, Chinn R, Raza W, Piper K, Pratt G, et al. (2008) Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow. Blood 112: 3293-3302.
41. Kieseier BC, (2011) The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 25: 491-502.
42. Rudick R, Polman C, Clifford D, Miller D, Steinman L, (2012) Natalizumab: Bench to Bedside and Beyond. Arch Neurol 5: 1-11.
43. Laichalk LL, Thorley-Lawson DA, (2005) Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 79: 1296-1307.
44. Farina A, Santarelli R, Gonnella R, Bei R, Muraro R, et al. (2000) The BFRF1 gene of Epstein-Barr virus encodes a novel protein. J Virol 74: 3235-3244.
45. Hislop AD, Taylor GS, Sauce D, Rickinson AB, (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617.
46. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, et al. (2007) Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27: 670-684.
47. Sauce D, Larsen M, Abbott RJ, Hislop AD, Leese AM, et al. (2009) Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infection. J Virol 83: 9068-9078.
48. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA, (2005) EBV and systemic lupus erythematosus: a new perspective. J Immunol 174: 6599-6607.
49. Larsen M, Sauce D, Deback C, Arnaud L, Mathian A, et al. (2011) Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS Pathog 7: e1002328 Epub 2011 Oct 20.
50. Comabella M, Kakalacheva K, Rio J, Münz C, Montalban X, et al. (2012) EBV-specific immune responses in patients with multiple sclerosis responding to IFNβ therapy. Mult Scler J 18: 605-609.
51. Frisullo G, Iorio R, Plantone D, Marti A, Nociti V, et al. (2011) CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment. Mult Scler 17: 556-566.
52. Means RE, Lang SM, Jung JU. (2007) Human gammaherpesvirus immune evasion strategies. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press. Chapter 31.
53. Jaquiéry E, Jilek S, Schluep M, Meylan P, Lysandropoulos A, et al. (2010) Intrathecal immune responses to EBV in early MS. Eur J Immunol 40: 878-887.
54. Malmeström C, Lycke J, Haghighi S, Andersen O, Carlsson L, et al. (2008) Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF. J Neuroimmunol 196: 159-165.
55. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, et al. (2000) Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192: 393-404.
56. Skulina C, Schmidt S, Dornmair K, Babbe H, Roers A, et al. (2004) Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A 101: 2428-2433.
57. Foxman EF, Iwasaki A, (2011) Genome-virome interactions: examining the role of common viral infections in complex disease. Nature Rev Microbiol 9: 254-264.
58. Recher M, Lang KS, Navarini A, Hunziker L, Lang PA, et al. (2007) Extralymphatic virus sanctuaries as a consequence of potent T-cell activation. Nat Med 13: 1316-1323.
59. Lycke J, Svennerholm B, Hjelmquist E, Frisén L, Badr G, et al. (1996) Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Neurol 243: 214-224.
60. Bech E, Lycke J, Gadeberg P, Hansen HJ, Malmeström C, et al. (2002) A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 58: 31-36.
61. Dreyfus DH, (2011) Autoimmune disease: A role for new anti-viral therapies? Autoimmun Rev 11: 88-97.
62. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58: 840-846.
63. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, et al. (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130: 1089-1104.
64. Miller G, Lipman MJ, (1973) Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Natl Acad Sci U S A 70: 190-194.
65. Lindsey JW, Hatfield LM, Crawford MP, Patel S, (2009) Quantitative PCR for Epstein-Barr virus DNA and RNA in multiple sclerosis. Mult Scler 15: 153-158.